The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.
作者信息
Califf Robert M, Kramer Judith M
机构信息
Duke Translational Medicine Institute, Durham, NC 27715, USA.
出版信息
Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):782-6. doi: 10.1002/pds.1617.
DOI:10.1002/pds.1617
PMID:18655016
Abstract
摘要
相似文献
1
The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.
Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):782-6. doi: 10.1002/pds.1617.
2
The long Avandia endgame.文迪雅漫长的终局。
Lancet. 2011 Jul 9;378(9786):113. doi: 10.1016/s0140-6736(11)61071-4.
3
The rosiglitazone story--lessons from an FDA Advisory Committee meeting.罗格列酮事件——美国食品药品监督管理局咨询委员会会议的教训
N Engl J Med. 2007 Aug 30;357(9):844-6. doi: 10.1056/NEJMp078167. Epub 2007 Aug 8.
4
Rosiglitazone and implications for pharmacovigilance.罗格列酮及其对药物警戒的意义。
BMJ. 2007 Jun 16;334(7606):1233-4. doi: 10.1136/bmj.39245.502546.BE.
5
The record on rosiglitazone and the risk of myocardial infarction.罗格列酮与心肌梗死风险的记录。
N Engl J Med. 2007 Jul 5;357(1):67-9. doi: 10.1056/NEJMe078116. Epub 2007 Jun 5.
6
After Avandia, some seek split in drug approval and monitoring.
Nat Med. 2010 Aug;16(8):831. doi: 10.1038/nm0810-831.
7
IOM urges FDA to be more aggressive in monitoring safety of approved drugs.
JAMA. 2012 Jun 20;307(23):2475-6. doi: 10.1001/jama.2012.5993.
8
Rosiglitazone and cardiovascular risk.罗格列酮与心血管风险。
N Engl J Med. 2007 Jun 14;356(24):2522-4. doi: 10.1056/NEJMe078099. Epub 2007 May 21.
9
The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.糖尿病药物的心血管安全性——来自罗格列酮经验的见解。
N Engl J Med. 2013 Oct 3;369(14):1285-7. doi: 10.1056/NEJMp1309610. Epub 2013 Sep 2.
10
Critics press FDA to act on evidence of rosiglitazone's cardiac safety issues.
JAMA. 2010 Jun 16;303(23):2341-2. doi: 10.1001/jama.2010.788.
引用本文的文献
1
Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.通过共享数据更新罗格列酮与心血管风险的认识：个体患者和汇总水平荟萃分析。
BMJ. 2020 Feb 5;368:l7078. doi: 10.1136/bmj.l7078.
Zotero 插件